SLC5A2 and hydrops fetalis: This study evaluated whether SGLT2 inhibitors reduce all-cause mortality and HF hospitalisations after TAVR.<h4>Methods</h4>A systematic search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was performed through April 2025 for studies comparing post-TAVR outcomes between SGLT2 inhibitor users and non-users.